US to lead Biocon Biologics' drive towards $1 billion revenue

The company is uniquely positioned in the US as it is the only Indian pharmaceutical firm with two commercialised biosimilars in the market

Biocon Biologics, the arm of biopharmaceutical major Biocon, which posted strong revenue growth of 31 per cent for the December quarter, will continue to be the growth driver for the Bengaluru-based company for the rest of the year, said its Chairperson and Managing Director Kiran Mazumdar-Shaw.

Also, the US will be the biggest driver to achieve a revenue target of $1 billion by 2021-22 financial year for the biologics business, said Christiane Hamacher, chief executive officer of the subsidiary. This will be followed by Europe and other global markets. 

“What is really encouraging is that a double-digit market share from biosimilar molecules